Abstract: Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.

Abstract: A pharmaceutical composition comprising a lipid component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms lipid carrying micelles having a lipophilic core comprising the lipid component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating ischemic conditions with reduced reperfusion injury.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2a receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable negatively charged agent wherein the microparticles optionally have a highly negative zeta potential of less than about ?40 mV. The invention also provides pharmaceutical compositions of the microparticles of the invention and methods of using the compositions of the invention to enhance an immune response in a patient in need thereof and as anti-cancer immunotherapy.

Abstract: Pharmaceutical compositions and methods of treatment or prevention of diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulation of the nitric oxide synthase pathway are provided, as are animal models and drug screening methods. Such modulation may be achieved by the administration of tetrahydrobiopterin (BH4) or its prodrugs and/or salts. Treating and preventing xerostomia can have the downstream effect of also preventing periodontitis, dental caries, parotid gland enlargement, inflammation and fissuring of the lips (chelitis), inflammation or ulcers of the tongue and buccal mucosa, oral candidiasis, salivary gland infection (sialadenitis), halitosis, and cracking and fissuring of oral mucosa.

Abstract: The present disclosure relates to an oxidising agent composition (M2), a packaging unit (kit of parts) comprising an agent for oxidative hair dyeing (M1) (dye component) and the oxidising agent composition (M2), a method for oxidative hair dyeing with use of the oxidising agent composition (M2), and the use of the oxidising agent composition for oxidative hair dyeing, for oxidative bleaching or lightening, and as fixing agent in a method for permanent shaping.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.

Abstract: A mixture, comprising at least three, two or four different chemical compounds, selected from the group eicosapentaenoic acid, usnic acid, norspermidine, clove oil and 10-undecynoic acid is used in dental health compositions. The mixture is used for dental hygiene for controlling Streptococcus mutans and Candida albicans.

Abstract: The present invention belongs to a technical field of nutrition additives for animal, and specifically discloses a nutrition supplement for animal, comprising eggs of an edible insect. Further, the eggs of the edible insect are one or more of eggs of Hermetia illucens L., eggs of Tenebrio molitor and eggs of fly. The present invention finds that the eggs of edible insect provide better effects such as enhancing nutrition, promoting growth and health care for animals, especially for newborn animals, weaning animals, weak animals or sick animals. The nutrition supplement provided by the present invention can be prepared easily and used conveniently. The present invention using the eggs of edible insect as a main component of the nutrition supplement can not only improve a health level of animals including livestock, aquatic animals and the like, but also enhance a feed intake, a feed conversion level and a comprehensive benefit of cultivation with a good application prospect.

Abstract: A liquid crystalline drug delivery system for ocular administration. The drug delivery system, which is mucoadhesive, biocompatible, non-irritating, and tissue permeable, contains nanoparticles stably dispersed in an aqueous solution and can be formulated for sustained release. Also provided are methods for producing the drug delivery system and methods for treating ocular disorders by administering it to a subject.

Abstract: The present invention wherein an oral composition contains Scutellaria root and Platycodon root. It is preferred that the oral composition further contains Rehmannia root. In the oral composition, when a content ratio of the Scutellaria root is defined as XA [mass %] and a content ratio of the Platycodon root is defined as XB [mass %], it is preferred that the following relation is satisfied: 0.00005?XB/XA?20000.

Abstract: The present invention relates to a tooth-attachable patch comprising: a drug layer for delivering drugs to a tooth; and a backing layer positioned on the opposite side of a tooth attachment surface of the drug layer, and including, both a water-soluble polymer and a water-insoluble polymer. The patch of the present invention can be easily removed by merely brushing the teeth without separately stripping off a backing layer.

Abstract: In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 2 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.

Abstract: A pesticide composition for controlling Fusarium head blight, which contains 1 to 150 parts by weight of jinggangmycin and 1 to 30 parts by weight of tebuconazole. The pesticide composition of the present invention has an obvious synergistic effect when used for controlling Fusarium head blight, can remarkably enhance the effect of controlling Fusarium head blight, and increase the ability of the human being in controlling Fusarium head blight of grain crops.

Abstract: Teeth can be hardened and made more resistant to acid damage if treated with compositions that allow for the remineralization and demineralization of minerals found in teeth. Exchanging ions in hydroxyapatite for fluoride or other metal ions can result in teeth that are more resistant to chemical and physical insults.

Abstract: A bone substitute material is disclosed consisting of a zirconium dioxide ceramic having preferably an open porosity. The bone substitute material can be used in particle form or in block form.

Abstract: Compositions are described comprising an amount of a toxicant comprising a compound of the formula HNR1R2, or a salt thereof, wherein R1 and R2 are independently hydrogen, a substituted or unsubstituted C4-C6-cycloalkyl group or a substituted or unsubstituted C6-C12-aryl group; wherein the amount of the toxicant is sufficient to control termites. Methods for controlling termites using such compositions are also described.

Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.